The $1 Billion Cannabis Drug Is Just Weeks Away. Here’s How We’ll Profit

When it comes to investing, there is nothing like identifying a massive change and finding the companies in the best positions to profit from it.

That’s exactly what’s about to happen with the $1 billion cannabis drug, set for FDA approval in June.

Whether you’ve followed Money Morning Defense and Tech Specialist Michael A. Robinson for years or are “meeting” him for the first time today, you have to agree that he really nailed one “cannabis drug” stock right on the head.

Since he first recommended GW Pharmaceuticals Plc. (Nasdaq ADR: GWPH) in 2014, the stock’s performance crushed the market, with nearly 100% gains compared to the S&P 500’s roughly 40% gain over that same span.

And that’s just the start for this marijuana stock.

Indeed, GW is beating the market so far this year 8.2% to 1.5%. Up market or down, this stock is killing it.

However, there is yet another catalyst coming in June that could be the biggest thing the stock has ever seen.

No doubt, legal cannabis is coming. Last year, the big news was California announcing it would go fully legal on Jan. 1, 2018. It’s a huge market, with 37 million people and a $2.5 trillion economy.

Wall Street also sees what’s happening. For example, Cowen & Co. recently forecasted that U.S. legal cannabis sales will hit $50 billion by 2026 and $75 billion by 2030.

GW has already released a cannabis-based mouth spray called Sativex to treat pain in multiple sclerosis patients. The drug was approved in the United Kingdom in 2010.

The company also has a pipeline of earlier-stage marijuana-based drugs that are focused on schizophrenia, autism, and other conditions. We expect the company to finish 2018 with roughly $400 million in the bank, enabling GW Pharma to become medical marijuana’s most dominant player.

And this upcoming cannabis drug will be the biggest catalyst yet. And it’s just weeks away from FDA approval.

Be Bullish – GW Pharma Is About to Explode Higher

Get ready for the first in a wave of new cannabis-based drugs.

GW’s newest product, Epidiolex, is a potential breakthrough to benefit the 3 million Americans who suffer from epilepsy. The FDA fast-tracked the drug candidate to treat newborn children with the disease, and Michael expects approval to come within weeks.

In fact, an FDA advisory committee unanimously recommended the agency approve the drug when it comes up for review in June.

In studies involving 750 children since 2015, 50% have shown a decrease in seizures with limited side effects. FDA approval will set the stage for a major windfall as this new drug changes lives – and changes attitudes about cannabis’ medical applications.

Some analysts think that, if approved, Epidiolex could hit the market in the United States by the fourth quarter of this year. And Goldman Sachs analysts forecasted worldwide sales of $2.2 billion for Epidiolex by 2025, with more than half of that coming from off-label use.

GW is one of the early adopters of cannabis technology, and it has the muscle to get things done. With the market for legal marijuana and cannabinoid-based drugs burgeoning, the sky is the limit for both the company and its investors.

*This has been a guest post by Money Morning*

 Related: Here’s How Baby Boomers Get Their Weed


Leave a Reply

Your email address will not be published. Required fields are marked *